摘要
目的:研究血小板激活因子拮抗剂BN52021对大鼠缺血再灌注肝脏的影响。方法:将大鼠分为三组,对照组未进行缺血及药物治疗;缺血再灌注组行40min缺血,然后行120min再灌注;血小板激活因子拮抗剂治疗组行40min缺血,120min再灌注,再灌注时给予BN52021(10mg/kg),比较各组血清SGPT、SGOT、AKP及γ-GT,肝脏的细胞能荷。结果:用血小板激活因子拮抗剂治疗组血清SGPT、SGOT、AKP、γGT均较缺血再灌注组显著降低,能荷水平明显升高。结论:血小板激活因子拮抗剂BN52021用于大鼠肝脏缺血再灌注可减少肝脏的损害,提示血小板激活因子(PAF)对肝脏缺血再灌注损伤的发生起一定的作用,血小板激活因子拮抗剂BN52021有可能用于肝脏缺血再灌注损伤的治疗。
Objective: Plateletactivating factor antagonist BN 52021 on ischemia-reperfusion(I/R)injury of rat liver was studied.Methods: Rats were divided into 3 groups.The normal control group was not subjected to hepatic ischemia and no treatment was given.The I/R injury group was subjected to 40 minutes of ischemia followed by reperfusion for 120 minutes.The AntiPAF treatment group was subjected of reperfusion and BN 52021 10 mg/kg was administered at reperfusion SGPT,SGOT,AKP and γGT and hepatic energy charge were compared.Results: The antiPAF treatment group serum levels of SGPT,SGOT,AKP and γGT were significantly lower than I/R injury group. Energy charge level was significantly higher with antiPAF treatment (P<0.05).Conclusion: AntiPAF BN 52021 treatment at reperfusion decreased damage of rat liver subjected to I/R injury.AntiPAF BN 52021 may be useful in the treatment of hepatic I/R injury.
出处
《河南医学研究》
CAS
1998年第1期10-13,共4页
Henan Medical Research